Revelation Biosciences, Inc. (REVB) stock
Close on Nov 12, 2026Market cap $2.99MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $2.99M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.41
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$12.16M
- EPS, diluted
- -$23.95
- Book value per share
- $12.93
- Diluted shares
- 1M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $4.36
- Open
- $4.27
- Day's range
- $4.15 – $4.40
- Volume
- 6,858
- Average volume (20 days)
- 27,755
- Beta (5 years)
- 1.24
- 52-week range
- $3.08 – $40.60
- RSI (14 days)
- 49.7
- Volatility (1 year)
- 83.7%
- Relative volume
- 0.66×
- WACC
- 11.2%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | REVB | S&P 500 | Difference | REVB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -19.2% | -2.7% | −16.5 pts | ||
| 3 months | -43.6% | -1.7% | −41.9 pts | ||
| Year to date | -80.4% | +11.9% | −92.3 pts | ||
| 1 year | -84.1% | +12.0% | −96.1 pts | ||
| 3 years | -100.0% | +78.2% | −178.2 pts | -94.2% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -95.0% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Revelation Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- News
- Results
- Results
About Revelation Biosciences
Pharmaceutical Preparations
Revelation is a clinical-stage biopharmaceutical company that develops therapeutic candidates to treat and prevent inflammatory conditions, focusing primarily on kidney disorders. The company's therapeutic pipeline is built upon its proprietary formulation platform known as Gemini, which utilizes a synthetic Toll-like receptor 4 agonist to rebalance dysregulated immune responses and reduce excess cellular inflammation. Its principal clinical-stage development programs include GEM-AKI for the treatment of acute kidney injury and GEM-CKD for the management of chronic kidney disease. Because its products remain in clinical and preclinical development, Revelation does not currently market commercial drugs, though its intended patient base consists of individuals suffering from severe acute or progressive renal illnesses.
Company profile, executives and historyRevelation Biosciences stock: common questions
What is Revelation Biosciences's stock price?
REVB closed at $4.38 on Nov 12, 2026, up 0.46% on the day. Over the past 52 weeks it traded between $3.08 and $40.60.
What is Revelation Biosciences's market cap?
Revelation Biosciences was worth $2.99M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is REVB's P/E ratio?
Revelation Biosciences lost money over fiscal 2025 (diluted EPS -$23.95), so it has no meaningful P/E ratio.
Does Revelation Biosciences pay a dividend?
No. Revelation Biosciences has not paid a cash dividend over the last twelve months.
When does Revelation Biosciences report earnings next?
Revelation Biosciences is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has REVB stock performed over the past year?
Including dividends, REVB returned -84.1% over the past year, against +12.0% for the S&P 500.
Who are Revelation Biosciences's competitors?
Companies most similar to Revelation Biosciences by business, industry and size include GRI, UNCY, ELDN, ACRS, VERA.
See a number that looks wrong?